Edity Therapeutics ’s Post

𝐍𝐚𝐯𝐢𝐠𝐚𝐭𝐢𝐧𝐠 𝐭𝐡𝐞 𝐑𝐍𝐀 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞: 𝐅𝐫𝐨𝐦 𝐁𝐞𝐧𝐜𝐡 𝐭𝐨 𝐁𝐞𝐝𝐬𝐢𝐝𝐞 The field of RNA therapeutics has emerged as one of the most exciting areas of drug development, offering a new dimension of precision medicine that could potentially target diseases at their genetic roots. A striking infographic provides a bird’s-eye view of the current RNA therapeutics landscape, categorizing companies according to their approach and highest stage of development. It's a vibrant ecosystem where ASOs/PMOs, RNAi, mRNA/RNA Aptamers, and other RNA molecules are being explored to create ground-breaking treatments. 𝐇𝐞𝐫𝐞’𝐬 𝐰𝐡𝐚𝐭 𝐭𝐡𝐞 𝐥𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞 𝐫𝐞𝐯𝐞𝐚𝐥𝐬 👇 𝐃𝐢𝐯𝐞𝐫𝐬𝐞 𝐀𝐩𝐩𝐫𝐨𝐚𝐜𝐡𝐞𝐬 Companies are leveraging various RNA-based technologies, from antisense oligonucleotides (ASOs) and RNA interference (RNAi), to mRNA therapies that have been propelled into the limelight by COVID-19 vaccines. 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭𝐚𝐥 𝐒𝐭𝐚𝐠𝐞𝐬 The graphic illustrates a progression from discovery/preclinical stages to approved therapies, with a handful of frontrunners having navigated the full journey to market authorization. 𝐀𝐩𝐩𝐫𝐨𝐯𝐞𝐝 𝐌𝐢𝐥𝐞𝐬𝐭𝐨𝐧𝐞𝐬 Notably, the 'Approved' section highlights industry giants like Pfizer, BioNTech SE and Moderna whose mRNA vaccines have revolutionized our response to pandemics. 𝐄𝐦𝐞𝐫𝐠𝐢𝐧𝐠 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐨𝐫𝐬 Numerous start-ups and biotech's are in early stages of research, suggesting a rich pipeline of potential therapies that may reshape our approach to complex diseases. 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐯𝐞 𝐏𝐫𝐨𝐠𝐫𝐞𝐬𝐬 The presence of multiple firms across different stages of development underscores the collaborative effort in the industry to bring RNA therapeutics to patients. What stands out is not just the sheer number of entities invested in RNA technology but the rapid progression from theoretical science to real-world applications. This is a testament to the commitment and rapid innovation within the pharmaceutical and biotech sectors. As we continue to witness the evolution of this dynamic field, it’s clear that the future holds promising advancements for patient care. The potential of RNA therapeutics to provide targeted, effective, and potentially curative treatments is a beacon of hope for many diseases that are currently difficult to treat. Kudos to the creators of this comprehensive visualization for capturing the essence of this transformative era in biomedicine. #RNATherapeutics #DrugDevelopment #Biotech #PharmaInnovation #PrecisionMedicine #Biotechnology #FutureOfHealthcare Formulation & Delivery by Oxford Global's RNA Therapeutics Event 👇https://hubs.la/Q02hHPNP0

Stories making headlines today in the biopharma industry: This past week has been pivotal for the biotech and pharmaceutical sectors, marked by significant advancements and strategic movements. Here’s a brief rundown of the notable developments: 1. The FDA has extended the use of Sarepta Therapeutics’ gene therapy, Elevidys, for Duchenne muscular dystrophy to include patients aged four and older. Originally approved for 4-5-year-old boys, this $3.2 million treatment now offers accelerated approval for wheelchair-dependent patients and full approval for others, providing new hope for families. 2. Lexicon Pharmaceuticals, Inc. resubmitted its type 1 diabetes medication to the FDA, nearly five years after it was initially rejected due to safety and efficacy concerns. This renewed application aims to address previous regulatory issues, potentially marking a milestone in diabetes treatment innovation. 3. Ginkgo Bioworks, Inc. and Xellia Pharmaceuticals have announced workforce layoffs, while Melodia Therapeutics has struck a $275 million partnership with Alivexis, Inc to enhance their research and development endeavors. 4. In an industry rarity, Tectonic Therapeutic, Inc. made its public market debut through a reverse merger, signaling cautious optimism despite a subdued market environment. 5. New genetic markers related to delaying Alzheimer’s onset have been identified, providing a promising new avenue for therapeutic intervention in this crucial field. 6. The US and EU have pledged over $2 billion to enhance vaccine manufacturing in Africa, aiming to bolster global health security and pandemic preparedness. 7. Zealand Pharma’s weight loss candidate, an amylin analog, has met early efficacy goals, marking a significant step forward in the fight against obesity as it moves through clinical trials. 8. Gilead Sciences has reported that its biannual injection for HIV prevention was fully effective in a Phase 3 study involving cisgender women, suggesting a potential transformation in HIV prophylaxis. 9. A promising antibody, after multiple tests by Gilead Sciences, has been acquired by a smaller biotech firm with a $40 million investment. The firm seeks to unlock the antibody’s full potential. These developments underscore the dynamic nature of the biotech and pharmaceutical industries, driven by innovation, strategic realignments, and groundbreaking research, heralding a future of potential breakthroughs and enhanced therapeutic solutions. #pharma #biotech #topstories #biodatastudio

Early career opportunity here.

UPDATED list of #MedicalScienceLiaison roles... --Maybe you are relaxing this weekend. --Maybe you are working a conference. --Maybe, like me, you are cleaning and organizing! Let's make it easy for you to see NEW JOB opportunities. A few territories have shifted so it was worth a quick post to update you. Quick Preview: --MSL Director, Oncology --MSLs in rare disease, immunology, and oncology nationwide Please share with your network to help #jobseeker candidates out there in #pharma and #biotech

Genome Sequencing and Pharmacogenetics: The Future of Medicine Genome sequencing and pharmacogenetics are rapidly transforming the landscape of healthcare, offering unprecedented opportunities for personalised and effective medicine. Genome Sequencing: Unlocking the Blueprint of Life * Early Disease Detection: By identifying genetic predispositions, individuals can take proactive steps to prevent or manage diseases like cancer, heart disease, and diabetes. * Drug Development: Genome sequencing accelerates drug discovery by identifying potential drug targets and predicting drug efficacy and safety. * Rare Disease Diagnosis: For patients with undiagnosed conditions, genome sequencing can provide crucial insights, leading to accurate diagnoses and targeted treatments. * Personalised Medicine: Understanding an individual's genetic makeup enables tailored treatment plans, increasing the likelihood of successful outcomes. Pharmacogenetics: Optimising Drug Therapy * Improved Drug Efficacy: By matching medications to a patient's genetic profile, doctors can select the most effective drugs and dosages, maximising therapeutic benefits. * Reduced Adverse Drug Reactions: Pharmacogenetics can help identify patients at risk of experiencing severe side effects, allowing for safer medication choices. * Cost-Effective Care: Preventing adverse drug reactions and optimising treatment plans can lead to significant cost savings in healthcare. * Accelerated Drug Development: Pharmacogenetics can streamline clinical trials by identifying patient populations most likely to respond to specific drugs. The Synergistic Power of Genome Sequencing and Pharmacogenetics * Precision Medicine: Combining these technologies creates a holistic approach to healthcare, allowing for highly individualised treatment plans. * New Therapeutic Targets: By identifying genetic variations linked to diseases, researchers can develop novel therapies targeting specific molecular pathways. * Population Health Management: Genome sequencing and pharmacogenetics can be used to assess population-level disease risks and inform public health strategies. Challenges and Considerations While the potential benefits are immense, it's important to address challenges such as data privacy, ethical implications, and the need for comprehensive genetic counseling. Additionally, further research is required to fully realise the potential of these technologies. In conclusion, genome sequencing and pharmacogenetics represent a promising future for medicine, offering the potential to revolutionise disease prevention, diagnosis, and treatment. As these technologies continue to advance, we can anticipate significant improvements in patient outcomes and overall healthcare quality.

𝐑𝐍𝐀 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐄𝐱𝐩𝐥𝐚𝐢𝐧𝐞𝐝: 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧𝐬 𝐢𝐧 𝐆𝐞𝐧𝐞 𝐒𝐢𝐥𝐞𝐧𝐜𝐢𝐧𝐠 & 𝐄𝐱𝐩𝐫𝐞𝐬𝐬𝐢𝐨𝐧 𝐄𝐱𝐩𝐥𝐚𝐢𝐧𝐞𝐝 RNA therapeutics refers to a class of pharmaceuticals that use ribonucleic acid (RNA) molecules to treat diseases by targeting specific genes or proteins. RNA therapeutics can be divided into several categories, including messenger RNA (mRNA), small interfering RNA (siRNA), and antisense oligonucleotides (ASOs). mRNA therapeutics are designed to deliver genetic instructions to cells, enabling them to produce proteins that can treat or prevent disease. 𝐒𝐚𝐦𝐩𝐥𝐞 𝐓𝐨𝐂: https://lnkd.in/g8fhHnXv The RNA therapeutics market is experiencing robust growth globally, with North America leading the market due to increased research activities and substantial funding availability. The market is driven by the rising prevalence of chronic diseases, such as cancer, genetic disorders, and infectious diseases, for which RNA-based therapies show promising results. In addition, advancements in RNA technology, including mRNA and siRNA, have expanded the potential applications of RNA therapeutics, driving market growth. The field of RNA therapeutics has witnessed significant advancements, particularly in the development of messenger RNA (mRNA) and small interfering RNA (siRNA) technologies. The mRNA technology, for instance, has revolutionized vaccine development, as demonstrated by the rapid development of mRNA COVID-19 vaccines. This technology can also be utilized for protein replacement therapies, where mRNA is used to instruct cells to produce missing or defective proteins, offering a promising approach for treating genetic disorders and other diseases. Chronic diseases, including cancer, genetic disorders, and infectious diseases, are becoming increasingly prevalent worldwide, leading to a growing demand for innovative treatment options. RNA therapeutics offer a promising solution, as they can target specific genes or proteins involved in disease pathways, providing a more targeted and potentially more effective approach compared to traditional treatments. 📢𝐆𝐞𝐭 𝑷𝑫𝑭 𝑪𝒐𝒑𝒚 : https://lnkd.in/gczZq-wM 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬 Advancements in Drug Delivery Systems  Gene Editing Technologies Advancements in RNA Technology  Increasing Prevalence of Chronic Diseases 𝐓𝐲𝐩𝐞 𝐨𝐟 𝐌𝐨𝐥𝐞𝐜𝐮𝐥𝐞 Replicating RNA (repRNA) Self Amplifying RNA (saRNA) Self Activating RNA (sacRNA) Self Activating mRNA (samRNA) Transfer RNA (tRNA) The RNA Society SIRNAOMICS CureVac BioNTech SE #RNATherapeutics #GeneTherapy #Biotechnology #PrecisionMedicine #DrugDevelopment #TherapeuticInnovation #GeneticMedicine #RNAInterference #mRNA #AntisenseTherapy #RNAi #RNASequencing #TherapeuticAdvancements #PrecisionTherapeutics #TherapeuticTargets

Unraveling Opportunities: Polyclonal Antibodies Market Insights Get To More: https://lnkd.in/gt5QEdsD Diverse Solutions in Immunotherapy: The Polyclonal Antibodies Market is witnessing a surge in demand driven by advancements in #immunotherapy. These #antibodies, sourced from multiple B cells, offer a diverse range of binding specificities, making them #valuable tools for targeting various diseases, #including cancer, #autoimmune disorders, and infectious diseases. As the medical community continues to uncover the intricacies of the immune system, polyclonal antibodies emerge as #versatile agents capable of tackling complex #therapeutic challenges with #precision and #efficacy. Expanding Applications Across Biomedical Research: Polyclonal antibodies play a pivotal role in #biomedical research, facilitating the detection, quantification, and isolation of target molecules in diverse experimental settings. From basic research in academia to drug discovery and development in the #pharmaceutical industry, these antibodies serve as indispensable tools for #understanding disease mechanisms, validating drug targets, and evaluating #therapeutic efficacy. Their versatility, high specificity, and #reproducibility make them indispensable assets in the quest for scientific #breakthroughs and #medical innovations. Navigating the Landscape of Personalized Medicine: In the era of personalized medicine, the Polyclonal #Antibodies Market is poised to play a crucial role in tailoring treatment approaches to #individual patient profiles. By leveraging the unique binding #specificities of polyclonal antibodies, researchers and clinicians can design highly personalized #therapeutic regimens that target specific disease pathways while minimizing off-target effects. As #precision medicine gains traction, the demand for #customized polyclonal #antibody-based therapies is expected to rise, driving innovation and #investment in this rapidly evolving field. Key players in the Polyclonal Antibodies Market: 1. Thermo Fisher Scientific Inc. 2. abcam plc 3. Merck KGaA, Darmstadt, Germany 4. Bio-Rad Laboratories, Inc. 5. F. Hoffmann-La Roche Ltd #PolyclonalAntibodies #Immunotherapy #BiomedicalResearch #TherapeuticSolutions #PrecisionMedicine #DrugDiscovery #Immunology #AntibodyTherapeutics #Biotechnology #MedicalInnovation #CancerTreatment #InfectiousDiseases #AutoimmuneDisorders #BiotechIndustry #HealthcareTech

📌 Future prospects for human genetics and genomics in drug discovery 📍 Introduction - Drug discovery productivity has declined, but genetics and genomics are starting to reverse this by improving success rates - Rare disease genetics enables therapy development and cancer genetics improves success rates by better understanding subtypes - Even subtle effects from genes influencing complex diseases double success rates vs unsupported targets 📍 Rare disease genetics - Identifying causal mutations enables targeted therapy development - E.g. exon skipping treatment for Duchenne muscular dystrophy to restore dystrophin protein reading frame - Rare mutations indicate whether inhibiting or activating a target may treat disease -Loss-of-function (LoF) mutations that protect suggest inhibitors, while LoF risk mutations suggest activators could treat - Rare mutations help predict efficacy and safety of modulating a target - E.g. PCSK9 LoF mutations lower cholesterol, while gain-of-function mutations increase early cardiovascular disease risk. This supported PCSK9 inhibitor development 📍 Common disease genetics - Genome-wide association studies (GWAS) identify subtle gene variants influencing complex disease risk - E.g CFH gene variants predispose to age-related macular degeneration, enabling complement inhibitor development - Allelic series cover a range of rare and common variants in one gene -They estimate dose-response between gene activity and phenotype which helped implicate Parkinson's disease gene LRRK2 as a drug target 📍 Key findings - Rare disease mutations help elucidate disease mechanisms and provide therapeutic hypotheses (e.g. exon skipping therapy for Duchenne muscular dystrophy) - Rare and common variants in the same gene (allelic series) help estimate dose-response relationship between target modulation and clinical impact (e.g LRRK2 mutations and Parkinson's disease risk) - Common disease GWAS implicate causal genes like CFH variants predisposing to age-related macular degeneration, enabling complement inhibitor drug development 📍 Future prospects - Larger scale sequencing will uncover more allelic series spanning the frequency/effect size spectrum, providing therapeutic hypotheses for nearly every gene - Increased worldwide population sequencing will enable detecting population-specific effects and improve fine-mapping resolution - Longitudinal cohorts will facilitate studying disease progression - Machine learning will integrate multidimensional genomics, molecular, and phenotypic data to elucidate gene-disease mechanisms and improve variant interpretation 📍 Conclusion - The value of human genetics for drug discovery will continue growing as larger scale sequencing studies reveal more alleles influencing disease risk across a scale of frequencies and effect sizes Happy reading. Would you add anything, please add in the comments section #bioinformatics #computationalbiology #genetics #drugdiscovery #sequencing

𝐔𝐧𝐝𝐞𝐫𝐬𝐭𝐚𝐧𝐝𝐢𝐧𝐠 𝐁𝐢𝐨𝐦𝐚𝐫𝐤𝐞𝐫𝐬: 𝐓𝐲𝐩𝐞𝐬 𝐚𝐧𝐝 𝐓𝐡𝐞𝐢𝐫 𝐈𝐦𝐩𝐨𝐫𝐭𝐚𝐧𝐜𝐞 Biomarkers are measurable indicators that can provide information about the biological state or condition of an organism. They play a crucial role in various fields like medicine, research, and drug development. Here are some types of biomarkers and their significance: 📚 𝐒𝐚𝐦𝐩𝐥𝐞 𝐓𝐨𝐂: https://lnkd.in/gN_t7Fvr Diagnostic Biomarkers: These biomarkers indicate the presence or absence of a disease. Examples include prostate-specific antigen (PSA) for prostate cancer and blood glucose levels for diabetes. Prognostic Biomarkers: These predict the likelihood of a disease progressing or the outcome of a disease. For instance, certain genetic markers can indicate the aggressiveness of certain cancers. Predictive Biomarkers: These help determine how a patient will respond to a particular treatment. Genetic markers that predict response to targeted therapies in cancer treatment are a good example. Surrogate Biomarkers: Instead of directly measuring clinical outcomes, these biomarkers are used as substitutes to predict clinical benefit. For example, cholesterol levels can be used as a surrogate for cardiovascular risk. Pharmacodynamic Biomarkers: These biomarkers measure the effect of a drug on the body. They can help in understanding the drug's mechanism of action and its potential side effects. Safety Biomarkers: These biomarkers indicate potential adverse effects or toxicity of a drug or treatment. Liver enzymes, for instance, can be monitored to assess potential liver damage due to medications. 📚𝐆𝐞𝐭 𝐌𝐨𝐫𝐞 𝐈𝐧𝐟𝐨: https://lnkd.in/gSrpEtsF Understanding these biomarker types is crucial for personalized medicine, where treatments can be tailored to individual patients based on their biomarker profiles. As biomarker research continues to advance, it holds the promise of revolutionizing healthcare by enabling early diagnosis, targeted treatment, and improved patient outcomes. 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬: Thermo Fisher Scientific Abbott Bio-Rad Laboratories PerkinElmer Merck Danaher Corporation Bristol Myers Squibb Agilent Technologies Roche Diagnostics UK & Ireland Pfizer Illumina QIAGEN Johnson & Johnson AstraZeneca Gilead Sciences Amgen #biomarkers #precisionmedicine #personalizedmedicine #genomics #proteomics #diagnostics #drugdiscovery #biotechnology #health #clinicalresearch #molecularbiology #pharmacogenomics #oncology #lifesciences #medicalresearch #genetics #bioinformatics #liquidbiopsy #genetictesting #immunoassay #neuroscience #metabolomics #biomarkerresearch #clinicaltrials #theranostics #pharmacodynamics